Iovance Biotherapeutics, Inc. (IOVA) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped IOVA stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Iovance Biotherapeutics is a high-growth biotech company focused on cell-based cancer therapies, primarily TIL therapies. The company has shown significant potential with FDA fast track status and strategic partnerships boosting its growth outlook. Despite ongoing challenges including patent disputes and regulatory hurdles, the company is well-positioned for significant advancements in personalized medicine. Analyst sentiment leans towards a BUY recommendation, supporting a generally bullish market outlook, with high growth expectations especially in the longer term. The saved 1-year distribution is P10 $10, P50 $16, and P90 $25.
Last analyzed · Model: gpt-4o
Iovance Biotherapeutics, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $10 | Pessimistic plausible scenario |
| P50 | $16 | Median scenario |
| P90 | $25 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Iovance Biotherapeutics is currently in a strong growth position with an 8260% revenue estimate growth primarily due to its treatment products gaining fast track FDA approval. Despite a negative average EPS surprise and some recent challenges, including patent issues and leadership changes, the positive catalysts such as collaborations with major oncology firms and expanding manufacturing capabilities skew the balance towards a bullish outlook over the next year. The analyst consensus is BUY, lending additional confidence to upward momentum.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this IOVA analysis generated?
September 30, 2026.
Is this a guaranteed IOVA prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full IOVA stock analysis · IOVA sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.